Gapping up
In reaction to earnings/guidance:
- LI +8.9%, NEGG +5.2%
Select index ETFs showing strength:
- IWM +1.2%, QQQ +0.9%, SPY +0.8%, DIA +0.7%
Select airline stocks trading higher:
- DAL +1.8%, SAVE +1.8%, UAL +1.6%, JETS +1.5%, AAL +1.4%, HA +1.3%, JBLU +0.9%, LUV +0.8%
Select oil/gas related names showing strength:
- USO +3.7%, RDS.A +2.8%, PSX +2.2%, SLB +2.1%, OIH +2%, HAL +2%, BP +1.8%, XLE +1.7%, TTE +1.5%, XOM +1.2%
Other news:
- KRYS +120.7% (topline results from GEM-3 pivotal trial for VYJUVEK for treatment of dystrophic Epidermolysis Bullosa)
- NRXP +51.4% (identifies significantly higher likelihood of surviving and recovering from critical COVID-19 in ZYESAMI® (aviptadil) treated patients previously administered remdesivir)
- APDN +34.9% (announced its COVID-19 diagnostic strategy in response to the emergence of Omicron (B.1.1.529), a newly identified SARS-CoV-2 variant of concern)
- ADGI +29.8% (reports that none of the mutations present in SARS-CoV-2 Variant, Omicron, are associated with escape from ADG20 neutralization in Vitro)
- MRNA +10.1% (Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant)
- RRD +8.7% ('go-shop" period expires)
- BNTX +4.7% (vaccine stock showing early strength)
- FLGC +4.6% (signed a licensing agreement with Tonino Lamborghini to produce and distribute Tonino Lamborghini branded cannabis beverages across North America and Colombia under their renowned luxury lifestyle brand)
- BCLI +3.7% (Presentation of New Analyses from the Phase 3 Trial of NurOwn in ALS at the 4th Annual ALS ONE Research Symposium)
- NVAX +3.5% (vaccine stock showing early strength)
- GRTS +3.2% (reports Omnicron variant has minimal impact on T cell epitopes)
- VET +3.1% (announces the acquisition of an incremental 36.5% interest in the Corrib Natural Gas Project; plans to reinstate a $0.06 per share quarterly dividend; provides budget/production guidance)
- XPEV +3% (in sympathy with LI earnings)
- KRON +2.8% (reports data from ongoing Phase 1/2 trial of oral CDK9 inhibitor KB-0742)
- NIO +2.3% (in sympathy with LI earnings)
Analyst comments:
- BMBL +3.5% (upgraded to Outperform from Mkt Perform at Raymond James)
- CPA +3% (upgraded to Strong Buy from Outperform at Raymond James)
- ARGX +2.8% (upgraded to Overweight from Neutral at Piper Sandler)
- TJX +2.2% (upgraded to Buy from Neutral at Citigroup)
- BURL +1.3% (upgraded to Buy from Neutral at Citigroup)